Monitoring of anticoagulation in aprotinin-treated patients during heart operation.
暂无分享,去创建一个
[1] T. Ebels,et al. Arterial revascularization with the right gastroepiploic artery and internal mammary arteries in 300 patients. , 1994, The Journal of thoracic and cardiovascular surgery.
[2] W. van Oeveren,et al. Alternative perioperative anticoagulation monitoring during cardiopulmonary bypass in aprotinin-treated patients. , 1994, Journal of cardiothoracic and vascular anesthesia.
[3] N. Tabuchi,et al. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass , 1993 .
[4] S. Westaby. Aprotinin in perspective. , 1993, The Annals of thoracic surgery.
[5] J. Fareed,et al. Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery. , 1993, The Annals of thoracic surgery.
[6] F. Loop,et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. , 1992, The Annals of thoracic surgery.
[7] R. Thisted,et al. In vitro effects of aprotinin on activated clotting time measured with different activators. , 1992, The Journal of thoracic and cardiovascular surgery.
[8] M. Yacoub,et al. Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass. , 1992, The Journal of thoracic and cardiovascular surgery.
[9] J. E. Doran,et al. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. , 1991, The Journal of thoracic and cardiovascular surgery.
[10] W. van Oeveren,et al. Increased anticoagulation during cardiopulmonary bypass by aprotinin. , 1990, The Journal of thoracic and cardiovascular surgery.
[11] R. Catane,et al. Tuftsin induces tissue factor-like activity in human mononuclear cells and in monocytic cell lines. , 1990, Blood.
[12] Steven D. Carson,et al. Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. , 1990, Blood.
[13] D. Cosgrove,et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). , 1989, The Journal of thoracic and cardiovascular surgery.
[14] W. van Oeveren,et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. , 1987, The Annals of thoracic surgery.
[15] F. Spencer,et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. , 1981, Annals of surgery.
[16] C. Kisker,et al. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. , 1978, The Annals of thoracic surgery.
[17] B. Bull,et al. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. , 1975, The Journal of thoracic and cardiovascular surgery.
[18] B. Bull,et al. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. , 1975, The Journal of thoracic and cardiovascular surgery.